Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Small Cell Lung Carcinoma 1Sarcoma 1Non-alcoholic Fatty Liver Disease 1Lymphoma 1Hypertension 1Hematologic Neoplasms 1Dyspnea 1Cardiotoxicity 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 17Trastuzumab 16Paclitaxel 15Doxorubicin 11Docetaxel 10Radiotherapy 9Carboplatin 9Capecitabine 9Bevacizumab 8Lapatinib 7Taxes 6Tamoxifen 6Gemcitabine 5Filgrastim 5Chemotherapy, Adjuvant 5sargramostim 4Sorafenib 4Radiation 4Neoadjuvant Therapy 4Granulocyte-Macrophage Colony-Stimulating Factor 4Vinorelbine 3Thiotepa 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Irinotecan 3Immunohistochemistry 3Granulocyte Colony-Stimulating Factor 3Erlotinib Hydrochloride 3Anastrozole 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms, Male × Lisinopril × Clear all
NCT01009918 2021-03-30

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

University of South Florida

Phase 2 Completed
468 enrolled 16 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡